A new formula for prostate cancer lymph node risk.

[1]  A. D'Amico,et al.  Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. , 2009, International journal of radiation oncology, biology, physics.

[2]  A. D'Amico,et al.  PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. , 2008, Urology.

[3]  J. Moul,et al.  Percent tumor involvement and risk of biochemical progression after radical prostatectomy. , 2008, The Journal of urology.

[4]  M. Soloway,et al.  Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. , 2008, Urology.

[5]  A. D'Amico,et al.  Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Epstein,et al.  A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. , 2008, The Journal of urology.

[7]  A. Haese*,et al.  A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer , 2008, BJU international.

[8]  Charles R. Thomas,et al.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.

[9]  Y. Yoshioka,et al.  Prostate Risk Index (PRIX) as a New Method of Risk Classification for Clinically Localized Prostate Cancer , 2007, Strahlentherapie und Onkologie.

[10]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[11]  F. Montorsi,et al.  Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer , 2006, BJU international.

[12]  Haiqun Lin,et al.  Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. , 2005, The Journal of urology.

[13]  Yan Yan,et al.  Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? , 2004, Urology.

[14]  Victor Reuter,et al.  A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. , 2003, The Journal of urology.

[15]  A. Heidenreich,et al.  Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.

[16]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[17]  J. Epstein,et al.  Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. , 2000, The American journal of surgical pathology.

[18]  A. D'Amico,et al.  Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[20]  E. Klein,et al.  Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. , 2008, Urology.

[21]  J. Epstein,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.

[22]  D. Bostwick,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. , 2001, Human pathology.

[23]  P. Carroll,et al.  Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.